This video is for instructional purposes only. The vaccine and diluent vials shown in this video may differ in appearance from actual vials of ProQuad and/or its accompanying diluent.

• ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella, and varicella in children 12 months through 12 years of age. ProQuad may be used in children 12 months through 12 years of age if a 2nd dose of measles, mumps, and rubella vaccine is to be administered.
  — At least 1 month should elapse between a dose of a measles-containing vaccine such as
  M-M-R^®_II (Measles, Mumps, and Rubella Virus Vaccine Live) and a dose of ProQuad.
  — If for any reason a second dose of varicella-containing vaccine is required, at least 3 months
  should elapse between administration of the 2 doses.

Select Safety Information

• ProQuad should not be administered to certain individuals, including those with any of the following: a history of anaphylactic reactions to neomycin; a history of hypersensitivity to gelatin or any other component of the vaccine; blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic system; an immunodeficient condition or receiving immunosuppressive therapy; active untreated tuberculosis; an active febrile illness (>101.3°F); or those who are pregnant.
• In clinical trials with ProQuad involving children 12 to 23 months of age, the most frequently reported injection-site adverse experiences (>1% of children) were pain/tenderness/soreness, erythema, swelling, ecchymosis, and rash. The most frequently reported systemic vaccine-related adverse experiences (>1% of children) were fever (>102°F), irritability, measles-like rash, varicella-like rash, rash (not otherwise specified), upper respiratory infection, viral exanthema, and diarrhea.
• In these trials, the only systemic vaccine-related adverse experiences that were reported at a significantly greater rate in individuals who received ProQuad than in individuals who received M-M-R^®_II and VARIVAX^® [Varicella Virus Vaccine Live (Oka/Merck)] were fever (>102°F [>38.9°C] oral equivalent or abnormal) (21.5% versus 14.9%, respectively), and measles-like rash (3.0% versus 2.1%, respectively).
• Febrile seizures have been reported in children receiving ProQuad. Consistent with clinical study data on the timing of fever and measles-like rash, an interim analysis of a postmarketing observational study in children (N = 14,263) receiving their first dose of vaccine has shown that febrile seizures occurred more frequently 5–12 days following vaccination with ProQuad (0.5 per 1000) when compared with data from children in a historical, age- and gender-matched, control group vaccinated with M-M-R^®_II and VARIVAX (N = 14,263) concomitantly (0.2 per 1000). In the 0–30 day time period following vaccination, the incidence of febrile seizures with ProQuad (1.0 per 1000) was not greater than that observed in children receiving M-M-R^®_II and VARIVAX concomitantly (1.3 per 1000).
• The duration of protection from measles, mumps, rubella, and varicella infections after vaccination with ProQuad is unknown.
• Vaccination with ProQuad may not offer 100% protection from measles, mumps, rubella, and varicella infection.
• Before administering ProQuad, please read the Prescribing Information.

ProQuad, M-M-R^®_II, and VARIVAX are registered trademarks of Merck & Co., Inc.